Skip to content Skip to sidebar Skip to footer

Healthcare Stocks

As ASX Reporting Season for FY25 Looms: Here’s An Investors Ultimate Guide

ASX Reporting Season is almost upon us once again. It is the most important time of the year for investors, a time many reconsider if their thesis still holds, many choose to buy into a stock or sell, some will receive dividends (either expectedly or unexpectedly) whilst others will be disappointed. While you may not…

ByNick SundichJuly 23, 2025

Is it possible for an investor to ‘time the market’ or is it just a myth?

Is it possible at all to time the market? Some will tell you it is possible, but they were probably just lucky and/or were not even trying to. Others will tell you it is not possible, but they are most likely trying to find an excuse to blame poor short-term performance. Let's take a serious look…

ByNick SundichJuly 21, 2025

How Trump’s Proposed 200% Tariffs Could Hit CSL (ASX:CSL) and Other Aussie Biotechs

Donald Trump's Tariffs Could Hit CSL and other Aussie Biotechs...it is a reality that is sinking in for many investors. One of the US President's latest proposals — a 200% tariff on imported pharmaceuticals — has sent shockwaves through the healthcare sector. And yes, that includes close allies like Australia. For investors in CSL (ASX: CSL)…

ByUjjwal MaheshwariJuly 17, 2025

Atomo Diagnostics investors are excited about their fair share from Lumos Diagnostics’ A$487m distribution deal

Wednesday 16 July 2025 was a great day for Atomo Diagnostics (ASX:AT1) investors as shares climbed up to 56% higher and closed 25% above the previous day's closing price. The catalyst was an A$487m deal signed by Lumos Diagnostics, one of Atomo's key business partners and investors believe the company will carve out some of…

ByNick SundichJuly 17, 2025

Trump’s Trade Threats: What ASX Investors Should Watch Across Sectors

As trade tensions flare under Donald Trump's leadership, the global economic landscape is once again facing turmoil. This time, Trump’s rhetoric has brought forward threats of higher tariffs on various imports, including pharmaceutical products and copper. While these threats may seem distant to Australian investors, the potential impacts are significant and should not be underestimated.…

ByUjjwal MaheshwariJuly 16, 2025

Here Are 4 Dogs of the ASX that will Bounce Back With a Vengeance in FY26, and 4 That Won’t

Have you ever heard the term Dogs of the ASX? It can either allude to the worst stocks in the ASX generally, or perhaps the investment strategy of buying these worst performing shares at the start of a new year (either a calendar or financial year), thinking they will rebound. Many will be considering this strategy,…

ByNick SundichJuly 14, 2025

SDI (ASX:SDI): Will slow and steady win the race?

If you're looking for a stock that'll make you a fortune, SDI (ASX:SDI) might not be the best one for you. But if you just want a stock that has little downside risk, it might be more appropriate - but we can only say might. Given the record of dental stocks on the ASX, you might…

ByNick SundichJuly 11, 2025

Orphan Drug Designation: What is it and why is it a big deal for biotech stocks?

While most small cap health stocks dream of commercialisation, healthcare companies at an early stage get excited about achieving Orphan Drug Designation. Achieving this won't be as meaningful to the bottom line as a stock receiving regulatory approval, but it is a big step nonetheless. If and when commercialisation is achieved, this will have been a…

ByNick SundichJuly 10, 2025

Botanix Pharmaceuticals (ASX:BOT): Did it deserve to crash over 50% earlier this week?

Botanix Pharmaceuticals (ASX:BOT) crashed over 50% back on Tuesday after an update that left investors disappointed. A crash of this magnitude would suggest the FDA knocked back its drug or that it failed a clinical trial. With Botanix having commercialised its treatment, neither was the case, so it'd have to be a pretty bad sales update.…

ByNick SundichJuly 9, 2025

Here are Our 11 Top ASX Stocks to Buy in FY26: 1 From Each Sector!

It is a New Financial Year, so it's time to outline 11 Top ASX Stocks to Buy in FY26. Why 11 you might ask? Because 11 is the number of 'GICS' (Global Industry Classification Sectors) on the ASX, and we're picking one from each sector. Our 11 Top ASX Stocks to Buy in FY26! Energy: Ampol…

ByNick SundichJuly 7, 2025

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

As ASX Reporting Season for FY25 Looms: Here’s An Investors Ultimate Guide

Is it possible for an investor to ‘time the market’ or is it just a myth?

How Trump’s Proposed 200% Tariffs Could Hit CSL (ASX:CSL) and Other Aussie Biotechs

Atomo Diagnostics investors are excited about their fair share from Lumos Diagnostics’ A$487m distribution deal

Trump’s Trade Threats: What ASX Investors Should Watch Across Sectors

Here Are 4 Dogs of the ASX that will Bounce Back With a Vengeance in FY26, and 4 That Won’t

SDI (ASX:SDI): Will slow and steady win the race?

Orphan Drug Designation: What is it and why is it a big deal for biotech stocks?

Botanix Pharmaceuticals (ASX:BOT): Did it deserve to crash over 50% earlier this week?

Here are Our 11 Top ASX Stocks to Buy in FY26: 1 From Each Sector!

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Add Your Heading Text Here